Abbott Laboratories
Here’s whether Abbott Laboratories (ABT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-4.07% over 10 days); RSI 71 — overbought, elevated pullback risk; weak 1-year return of -32.0%; 3-month momentum negative (-19.2%). Currently 34.5% off its 52-week high. Score: -7/7.
ABT is trading below its 200-day MA ($115.55) — a key warning sign the longer-term trend is under pressure. With an RSI of 70.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -32.0% compares to +24.4% for SPY (trailed the market by 56.4%). The current 34.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.